Middle East and Asia Pacific Biotechnology Market to Surpass USD 1,080 Billion by 2033

Technological Innovations and Rising R&D Investments to Drive Middle East and Asia Pacific Biotechnology Market to USD 1,080 Bn by 2033 – Coherent Market Insights

The Middle East and Asia Pacific Biotechnology Market, by Technology (Nanobiotechnology, Tissue Engineering and Regeneration, Fermentation, Cell Based Assay, CRISPR, and Others ), by Application (Molecular Biology, Gene Synthesis, Gene Editing, Mammalian Protein Expression, Recombinant Antibody Expression, Peptide Synthesis, Protein Expression, Monoclonal and Polyclonal Antibody Generation, and Others), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, and Others), and by Region (Asia Pacific and Middle East), is estimated to be valued at USD 718.5 Bn in 2026 and expected to exhibit a CAGR of 14.2% during the forecast period (2026–2033).

The increasing number of biotech product launches by key market players is expected to drive growth of the Middle East and Asia Pacific biotechnology market during the forecast period. For instance, in June 2019, Synthego, a global genome engineering solutions company with its presence in Asia Pacific region, announced the launch of the Gene Knockout Kit v2. This is the only product that leverages a novel bioinformatics-powered multi-guide strategy to guarantee a gene knockout. The kit will accelerate research by saving scientists from multiple trial-and-error cycles in optimizing their CRISPR (Clustered regularly interspaced short palindromic repeats) experiment.

The increasing number of partnerships between market players is expected to propel growth of the Middle East and Asia Pacific biotechnology market during the forecast period. For instance, in June 2019, GlaxoSmithKline Plc, a U.K.-based healthcare company with its presence in Middle East and Asia Pacific, announced its collaboration with the University of California (UC), in order to establish a new lab that focuses on speeding up discovery of new gene-based treatments by developing new CRISPR-based technologies and exploring how gene mutations lead to any disease.

Browse 106 Market Data Tables and 132 Figures spread through 415 Pages and in-depth TOC on Middle East and Asia Pacific Biotechnology Market, by Technology (Nanobiotechnology, Tissue Engineering and Regeneration, Fermentation, Cell Based Assay, CRISPR, and Others ), by Application (Molecular Biology, Gene Synthesis, Gene Editing, Mammalian Protein Expression, Recombinant Antibody Expression, Peptide Synthesis, Protein Expression, Monoclonal and Polyclonal Antibody Generation, and Others), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions and Others), and by Region (Asia Pacific and Middle East)

To know the latest trends and insights prevalent in the Middle East and Asia Pacific biotechnology market, click the link below:

https://www.coherentmarketinsights.com/market-insight/middle-east-and-asia-pacific-biotechnology-market-4937

Key News

• In November 2025, Teijin Limited, a Japanese technology company and BioVaram, the brand name of UR Advanced Therapeutics, signed a business alliance on November 13, 2025, to expand access to regenerative medicine and implantable medical devices in India and Japan. The partners will explore Indian regulatory approval and commercialization of Teijin’s SYNFOLIUM cardiovascular repair patch, introduce J-TEC regenerative medicine products in India, and support BioVaram’s exosome, ECM-mimic and atelocollagen technologies in Japan.
• In July 2026, Sanyou Biopharmaceuticals Co., Ltd., and Guangzhou Baiyunshan Xihe Health Pharmaceutical signed a strategic cooperation agreement to co-develop innovative radiopharmaceuticals and radiodiagnostic products. The collaboration combines Sanyou Bio’s AI-STAL molecule libraries and SAI-DA drug accelerator with Baiyunshan Xihe’s radionuclide production, GMP manufacturing and clinical translation capabilities. The partners aim to build an end-to-end AI-driven molecular discovery-to-clinical translation platform for precision oncology diagnosis and therapy, supporting China nuclear medicine market growth.
• In July 2026, MGI Tech’s subsidiary Genoria AI, in collaboration with Shanghai AI Laboratory, launched ProtoPilot and BioLab Bench to advance Physical AI in life sciences. ProtoPilot is a self-evolving multi-agent system covering protocol design, code generation, device execution, and wet-lab feedback, while BioLab Bench evaluates AI agents on real automated lab tasks. ProtoPilot achieved 52.38% on ProtocolQA, nearing human expert performance and supporting progress toward unattended intelligent laboratory operations.
• In February 2026, World Health Expo Dubai launched a dedicated Biotech & Life Sciences Zone, positioning the UAE as a regional platform for advanced therapeutics, synthetic biology, AI-driven R&D, translational science, and sustainable biomanufacturing. The programme convened global experts, policymakers, investors, and regional innovators to accelerate partnerships and commercialization, while highlighting the Middle East’s growing role in turning laboratory research into real-world healthcare solutions for regional populations and new markets. (Source: World Health Expo Dubai)
• In June 2026, Abu Dhabi’s Department of Health signed strategic agreements with Children’s Hospital of Philadelphia, Mammoth Biosciences, and Arbor Biotechnologies to advance gene-editing therapies for rare and inherited diseases. Built on the Emirati Genome Program, the collaborations aim to strengthen clinical research, scientific expertise, advanced therapeutics, and future manufacturing capabilities, helping translate population-scale genomic insights into targeted treatments and clinical impact across the Middle East’s healthcare ecosystem for patients.

Key Takeaways of the Middle East and Asia Pacific Biotechnology Market

• The Middle East and Asia Pacific biotechnology market is expected to exhibit a CAGR of 14.2% over the forecast period (2026–2033). Asia Pacific is expected to account for a major market share over the forecast period (2026–2033), owing to increasing strategic licensing agreements by market players. For instance, in July 2021, Biocon Biologics Ltd., a fully integrated biosimilar company and a subsidiary of Biocon Ltd., announced that the U.S.-based Adagio Therapeutics granted an exclusive license to Biocon Biologics to manufacture and commercialize an antibody treatment based on ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, for India.
• Moreover, launches of new initiatives by market players to support molecular biology research and services in Middle East region will aid in growth of the Middle East and Asia Pacific biotechnology market. For instance, in February 2019, Neuberg Diagnostics, an India-based diagnostic company, and OptraSCAN Inc., a U.S.-based global digital pathology solutions provider, announced the launch of Global TELEPath Network for the pathologist community in South Africa, UAE, and India. Moreover, this network was launched under a new joint venture named Neuberg DIGIPATH, which is powered by OptraSCAN Inc.
• Some of the major players operating in the Middle East and Asia Pacific biotechnology market include Abbott Laboratories, Pfizer Inc., Abbvie Inc., Biocon, F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Astrazeneca Plc., Illumina, Inc., Sanofi S.A., Qiagen, Twist Bioscience, Thermo Fisher Scientific Inc., Biointron, Merck & Co., Inc., Sino Biological Inc., GeneWiz (Azenta Life Sciences), Danaher Corporation, and Synbio Technologies.